<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651920</url>
  </required_header>
  <id_info>
    <org_study_id>EOC-HRD2</org_study_id>
    <nct_id>NCT04651920</nct_id>
  </id_info>
  <brief_title>A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer</brief_title>
  <official_title>A Study on Association Between Homologous Recombination Genes and the Homologous Recombination Deficiency Status in Chinese Population With Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The association between homologous recombination (HR) gene mutations and homologous&#xD;
      recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients is&#xD;
      little known. This study would recruit 400 Chinese EOC patients with known targeted gene&#xD;
      mutations via a multi-panel testing of 27 genes, including BRCA1/BRCA2. All patients accept&#xD;
      evaluation of HRD model, which is based on the loss of heterozygosity (LOH), telomere allele&#xD;
      imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model&#xD;
      and their relationship with the prognosis, would provide a full description of for the&#xD;
      Chinese EOC patients, and a potential explanation of platinum-resistance in such population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">November 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Homologous recombination deficiency (HRD) score</measure>
    <time_frame>Two years</time_frame>
    <description>The HRD score for individual patient is a scale describing her HRD status. The score model is calculated by the analysis for three types of important molecular mechanism: loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The minimum value is 0, but the maximun value is not available. Higher scores mean more sensitivity to poly-ADP-ribose polymerase inhibitor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Five years</time_frame>
    <description>Progression-free survival in recruited patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Five years</time_frame>
    <description>Overall survival in recruited patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Chinese</condition>
  <condition>Homologous Recombination Deficiency</condition>
  <condition>BRCA1 Mutation</condition>
  <condition>BRCA2 Mutation</condition>
  <condition>Prognosis</condition>
  <condition>Homologous Recombination Genes</condition>
  <arm_group>
    <arm_group_label>Epithelial ovarian cancer patients sensitive to platinum based chemotherapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Epithelial ovarian cancer patients resistant to platinum based chemotherapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Evaluation of homologous recombination deficiency score</intervention_name>
    <description>Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)</description>
    <arm_group_label>Epithelial ovarian cancer patients resistant to platinum based chemotherapy</arm_group_label>
    <arm_group_label>Epithelial ovarian cancer patients sensitive to platinum based chemotherapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All patients accept evaluation of homologous recombination deficiency model.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese population with confirmed diagnosis of epithelial ovarian cancer with known&#xD;
        targeted gene mutations via a multi-panel testing of 27 genes and known resistance to&#xD;
        platinum-based chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Pathological confirmation of epithelial ovarian cancer&#xD;
&#xD;
          -  With available tumor tissues&#xD;
&#xD;
          -  Given consents to participate the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not meeting all of the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+8613911988831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Wu, M.D.</last_name>
    <phone>+8613810224549</phone>
    <email>wuming@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>8613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

